BridgeBio Pharma Pre-Paid Expenses 2018-2024 | BBIO

BridgeBio Pharma pre-paid expenses from 2018 to 2024. Pre-paid expenses can be defined as a current asset created by prepayment of costs and expenses for which the benefits will occur at a future date.
BridgeBio Pharma Annual Pre-Paid Expenses
(Millions of US $)
2023 $24
2022 $22
2021 $32
2020 $36
2019 $20
2018 $9
2017 $
BridgeBio Pharma Quarterly Pre-Paid Expenses
(Millions of US $)
2024-09-30 $38
2024-06-30 $28
2024-03-31 $28
2023-12-31 $24
2023-09-30 $23
2023-06-30 $21
2023-03-31 $25
2022-12-31 $22
2022-09-30 $26
2022-06-30 $33
2022-03-31 $34
2021-12-31 $32
2021-09-30 $32
2021-06-30 $27
2021-03-31 $26
2020-12-31 $36
2020-09-30 $27
2020-06-30 $21
2020-03-31 $20
2019-12-31 $20
2019-09-30 $22
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $4.392B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.350B 6.35
Dr Reddy's Laboratories (RDY) India $11.677B 22.35
Bausch Health Cos (BHC) Canada $3.009B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.142B 12.88
Supernus Pharmaceuticals (SUPN) United States $1.978B 26.93
Taysha Gene Therapies (TSHA) United States $0.447B 31.14
Personalis (PSNL) United States $0.239B 0.00
Assembly Biosciences (ASMB) United States $0.094B 0.00
Sol-Gel Technologies (SLGL) Israel $0.013B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00